BioSpace News Archive

Diomics Corporation, a leader in forensic, diagnostic, and therapeutic science since 2009, today announced that it has developed intellectual property and patents related to the identification of airborne pathogens.

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company’s Phase 2 trial of serlopitant for the treatment of pruritus associated with psoriasis in the Journal of the American Academy of Dermatology (JAAD).

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the expansion of its senior leadership with two new strategic hires, Kristen Stants as Chief People Officer and Li Malmberg, Ph.D., as Senior Vice President, Head of Manufacturing.

Informa Markets, the organiser of FHA-HoReCa, today announced that it will postpone the event to 13-16 July 2020 at Singapore Expo due to the evolving 2019 novel coronavirus situation.

Neogen Corporation (NASDAQ: NEOG) announced today that it has entered into a partnership with food industry blockchain pioneer Ripe Technology (ripe.io) to adapt innovative blockchain technology for use with Neogen’s food safety diagnostics and animal genomics.

- In this large Phase 3 study, RINVOQ™ (upadacitinib; 15 mg and 30 mg, once daily) met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis[1]

MIRAMAR, Fla., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation is proud to announce the appointment of Dr. Carol Nacy, PhD to the NuGenerex Immuno-Oncology (NGIO) Board of Directors.

BOSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to purchase up to an additional 4,173,912 shares of common stock at the public offering price, less the underwriting discounts and commissions.

INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company focused on treating infertility with its FDA-cleared INVOcell ® product, today announced receipt of Institutional Review Board (IRB) approval to commence its planned clinical trial to evaluate the modified INVOcell system for effectiveness of achieving fertilization,

A new study by scientists from India, USA, and UK has presented clinical evidence for an innovative test that can detect clusters of cancer cells in the blood of asymptomatic individuals as a non-invasive screening and diagnostic test.